Notice of Intent to Sole Source – Illumina
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH) intends to award a fixed-price purchase order on a sole source basis to Illumina, Inc. for the Illumina MiSeq i100 System. This system is required by the Department of Transfusion Medicine (DTM) to support clinical research and diagnostic assay development for transfusion-transmitted pathogens. This is a notice of intent, not a solicitation. Responses from interested parties are due by May 14, 2026, at 10 A.M. EST.
Scope of Requirement
The acquisition is for an Illumina MiSeq i100 System, which must support high-quality sequencing data generation from clinical specimens (viral RNA/DNA, host-derived nucleic acids). Applications include targeted sequencing, viral genome sequencing, and assay development workflows. Functional requirements include high data accuracy, low- to moderate-throughput, rapid turnaround times, flexible run configurations, cost-efficiency for smaller-scale applications, integrated workflows, ease of use, and compatibility with existing lab methods.
Contract & Timeline
- Contract Type: Fixed-Price Purchase Order
- Period of Performance: June 1, 2026 – May 31, 2027
- Authority: FAR Part 13 (Simplified Acquisition Procedures), Subpart 13.106-1(b)(1) for sole source under the Simplified Acquisition Threshold (SAT).
- NAICS Code: 334516 – Analytical Laboratory Instrument Manufacturing
- Response Due: May 14, 2026, 10 A.M. EST
- Published: May 4, 2026
Eligibility & Evaluation
This acquisition is not set aside for small businesses. The NIH intends to award to Illumina, Inc. as the original manufacturer and deemed the only source reasonably available. Interested parties may identify their interest and capabilities in response to this notice. Responses should include unit price, list price, shipping/handling, delivery period, prompt payment terms, F.O.B. Point, Unique Entity Identifier (UEI), Taxpayer Identification Number (TIN), and certification of business size. All offerors must have an active SAM.gov registration. The government reserves the discretion to conduct a competitive procurement based on responses.
Contact Information
For inquiries or to submit responses, contact Gregory Noland at gregory.noland@nih.gov.